NovoCure (NVCR) Income from Continuing Operations (2014 - 2026)
NovoCure (NVCR) posted quarterly Income from Continuing Operations of 15658000.0 for Q2 2026, up 60.99% year-on-year from 9726036.24 in Q2 2025, and up 77.99% on a QoQ basis from 71138000.0 in Q1 2026.
NovoCure (NVCR) Income from Continuing Operations (2014 - 2026) Analysis & Trends
NovoCure (NVCR) has reported Income from Continuing Operations for 13 consecutive years, with 15658000.0 the latest figure, recorded in Q2 2026.
- Quarterly Income from Continuing Operations rose 60.99% year-over-year to 15658000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 148565000.0 (up 13.09% YoY) and the FY2025 annual result came in at 136227000.0, up 19.21% from the prior year.
- Income from Continuing Operations advanced to 15658000.0 in Q2 2026 per NVCR's latest filing, from 71138000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for NVCR reached as high as 4647000.0 in Q1 2022 and fell as low as 71138000.0 in Q1 2026.
- A 5-year average of 38401500.0 and a median of 37286500.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations slumped 1041.83% — and 2025, when it jumped 62.84%.
- Year by year, Income from Continuing Operations stood at 37303000.0 in 2022, then slipped by 26.21% to 47079000.0 in 2023, then sank by 40.02% to 65922000.0 in 2024, then soared by 62.84% to 24499000.0 in 2025, then surged by 36.09% to 15658000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 15658000.0, 71138000.0, and 24499000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | NovoCure | 2.28 Bn | 1.85 Bn | 142.48 Mn | -15.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.66 Mn |
| Mar 31, 2026 | -71.14 Mn |
| Dec 31, 2025 | -24.50 Mn |
| Sep 30, 2025 | -37.27 Mn |
| Jun 30, 2025 | -40.14 Mn |
| Mar 31, 2025 | -34.32 Mn |
| Dec 31, 2024 | -65.92 Mn |
| Sep 30, 2024 | -30.57 Mn |
| Jun 30, 2024 | -33.38 Mn |
| Mar 31, 2024 | -38.76 Mn |
| Dec 31, 2023 | -47.08 Mn |
| Sep 30, 2023 | -49.49 Mn |
| Jun 30, 2023 | -57.42 Mn |
| Mar 31, 2023 | -53.06 Mn |
| Dec 31, 2022 | -37.30 Mn |
| Sep 30, 2022 | -26.58 Mn |
| Jun 30, 2022 | -24.01 Mn |
| Mar 31, 2022 | -4.65 Mn |
| Dec 31, 2021 | -26.46 Mn |
| Sep 30, 2021 | -13.12 Mn |